Delving into the Latest Updates on ARVAC-CG vaccine(Laboratorio Pablo Cassara S.R.L.) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target

SARS-CoV-2 antigen

Action

inhibitors

Mechanism

SARS-CoV-2 antigen inhibitors

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Laboratorio Pablo Cassara Srl

Active Organization

National University of General San MartínLaboratorio Pablo Cassara Srl

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The objective of this clinical trial is to test a new vaccine against SARS-CoV-2 (ARVAC-CG) in healthy adult volunteers, previously vaccinated against the SARS-CoV-2 virus.
The main questions it aims to answer are:
* What is the safety and tolerability profile of the two-dose schedule of this new vaccine?
* What is the immune response after each dose of vaccine Participants will receive two doses of the study vaccine 28 days apart. They will be required to complete a total of 7 safety and immunogenicity follow-up visits over a 1-year period.

Start Date20 Apr 2022

Sponsor / Collaborator

Laboratorio Pablo Cassara Srl

[+1]

100 Clinical Results associated with ARVAC-CG vaccine(Laboratorio Pablo Cassara S.R.L.)

Login to view more data

100 Translational Medicine associated with ARVAC-CG vaccine(Laboratorio Pablo Cassara S.R.L.)

Login to view more data

100 Patents (Medical) associated with ARVAC-CG vaccine(Laboratorio Pablo Cassara S.R.L.)

Login to view more data

100 Deals associated with ARVAC-CG vaccine(Laboratorio Pablo Cassara S.R.L.)

Login to view more data